Millendo Therapeutics is a fertility company, engaged in developing proprietary treatments for female infertility based on scientific discoveries about the existence of egg precursor, or EggPCsm, cells. EggPC cells are undifferentiated germ cells from fetal development that may have the capacity to mature into eggs. Co.'s portfolio of treatment options uses its patented technology, including proprietary methods to isolate EggPC cells from a woman's own ovarian tissue. Co.'s other treatment include: OvaPrime, which is a fertility treatment that could help restore a woman's egg production; and OvaTuresm, which is a potential fertility treatment that eliminates the need for hormone stimulation. The OVAS average annual return since 2012 is shown above.
The Average Annual Return on the OVAS average annual return since 2012 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OVAS average annual return since 2012 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OVAS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
